Introduction {#Sec1}
============

The continuous glucose monitoring (CGM) system is a very useful tool in the management of patients with insulin-treated diabetes, particularly type 1 diabetes (T1D) \[[@CR1]\]. The system was developed to assess glycemic variability with the aim of improving the degree of metabolic control of diabetes to reduce the risk of both chronic complications and episodes of hypoglycemia \[[@CR2], [@CR3]\]. Recent studies have confirmed the beneficial effects of CGM not only on metabolic control, but also on overall treatment satisfaction and quality of life of children with T1D \[[@CR4], [@CR5]\]. Many attempts have also been made to use CGM to predict diabetes mellitus in children with hyperglycemia \[[@CR6], [@CR7]\]. Interestingly, CGM can also be helpful in differentiating between types of diabetes, such as in patients with monogenic diabetes \[[@CR8]\].

One of the syndromic forms of monogenic diabetes in children and adolescents is the autosomal recessively inherited Wolfram syndrome (WFS), for which the clinical criteria have been clearly defined as coexistence of diabetes mellitus and optic atrophy. Because WFS is a neurodegenerative disorder, most WFS patients suffer also from diabetes insipidus, deafness, and many other multi-organ abnormalities \[[@CR9], [@CR10]\]. Diabetes in WFS patients is non-autoimmune type of diabetes \[[@CR9]\]. However, it is associated with insulin deficiency due to selective loss of pancreatic β-cells and impaired insulin secretion \[[@CR10], [@CR11]\]. Studies performed in animal models confirmed that wolframin---the product of the *WFS*-*1* gene---is selectively produced by the β-cells of the pancreas, and islets deprived of its expression are more prone to apoptosis \[[@CR12], [@CR13]\]. To date, the studies that have characterized the course of diabetes in WFS patients have shown inconsistent results concerning the degree of metabolic control (based on HbA1c level) and insulin requirement in comparison with T1D patients \[[@CR14], [@CR15]\].

The aim of the present study was to evaluate glycemic variability using the CGM system in pediatric patients with insulin-treated diabetes in WFS versus pediatric patients with autoimmune T1D.

Materials and methods {#Sec2}
=====================

The study protocol was approved by the University Bioethics Committee at the Medical University in Lodz, Poland (RNN/133/10/KE). Patients and/or their parents gave written informed consent for participation in the study.

CGM was performed in two groups of patients: patients with WFS (*n* = 7; all females) and a 3:1 matched group of patients with T1D. Diagnosis of WFS was confirmed by direct sequencing of the *WFS1* gene and/or multiplex ligation-dependent probe amplification (MLPA; SALSA MLPA P163 GJB-WFS1 probemix, MRC-Holland, The Netherlands), as described previously \[[@CR16]\].

The T1D group was selected using propensity score matching from all available females who underwent CGM procedures in pediatric diabetology centers in Lodz or Gdansk (*n* = 75). Propensity score matching was performed for age, duration of diabetes, glycated hemoglobin level, and average daily insulin dose. The resulting group of 21 girls was used in the analysis. All patients had diabetes mellitus recognized according to WHO criteria. Autoantibodies specific for T1D were detected only in patients with T1D. All seven patients with WFS and 19 of 21 patients with T1D were treated with continuous subcutaneous intensive insulin therapy. HbA1c was determined by high-performance liquid chromatography (HPLC) using the *Bio*-*Rad VARIANT*™*Hemoglobin A1c Program* (*Bio*-*Rad Laboratories, Inc*. Hercules, CA, USA) with its values represented as percentages and mmol/mol.

In all studied patients, a 72-h record of CGM using an iPro2 device (Medtronic MiniMed, Inc., Northridge, CA, USA) was generated. CGM sensor insertion was performed in the diabetes clinic by trained study personnel.

For analysis of the results obtained within at least one complete day, the application "GlyCulator" was used \[[@CR17]\], which is available online ([www.pediatria.umed.pl/team/glyculator](http://www.pediatria.umed.pl/team/glyculator)). The following glycemic variability indices were evaluated in all patients: mean, standard deviation (SD), coefficient of variation (CV), M100 index, and J index as the measures of stability and quality of glycemic control; percentages of results above values of 126 and 180 mg/dL and below 70 and 54 mg/dL; and continuous overall net glycemic action (CONGA) \[[@CR17]\]. CONGA values represent the SD of differences between the current observation and the observation n hours prior (i.e., CONGA1h = 1 h prior, CONGA2h = 2 h prior, CONGA4h = 4 h prior, CONGA6h = 6 h prior) \[[@CR5]\].

In addition, C-peptide serum levels were estimated by applying the commercially available electrochemiluminescence method (ECLIA) (Roche Diagnostics GmbH, Germany). Fasting C-peptide levels from healthy individuals ranged from 1.1 to 4.4 ng/mL, and the detection limit has been assessed as 0.01 ng/mL for the assay.

Statistical analysis {#Sec3}
--------------------

Normally distributed data were represented using means with standard deviations and were compared using Welch's *t* test. Non-normally distributed variables were presented as medians with lower and upper quartile boundaries and compared between the groups using the Mann--Whitney *U* test. Results with *p* levels \<0.05 were considered as statistically significant. Analyses were performed using Statistica 10.0 PL software (Statsoft, Tulsa, OK, USA).

Results {#Sec4}
=======

The patients from the two study groups were matched based on sex and age (\~13.5 years) and had similar HbA1c levels (\~7.8 %), insulin requirements (\~0.7 U/kg), insulin bolus/basal ratio, and long-term duration of diabetes (\~8 years). However, WFS patients showed a significantly higher C-peptide level than T1D patients (*p* = 0.006). Characteristics of the study groups are shown in Table [1](#Tab1){ref-type="table"}.Table 1Clinical characteristics of matched WFS and T1D patientsWFST1D*p* level*N* Mean ± SD*N*Mean ± SDAge (years)713.58 ± 4.122113.85 ± 2.920.849Diabetes duration (years)78.08 ± 3.80218.20 ± 3.100.933HbA1c (%NGSP/mmol/mol IFCC)77.80 ± 1.05/58.70 ± 11.90217.76 ± 1.07/61.30 ± 12.000.943Insulin requirement (U/kg of body weight)70.68 ± 0.19210.74 ± 0.310.611Insulin bolus/basal ratio70.70 ± 0.38210.66 ± 0.120.774C-peptide (ng/mL)70.31 ± 0.20210.04 ± 0.04**0.006***p* value below 0.05 is marked in bold*T1D* type 1 diabetes, *WFS* Wolfram syndrome, *SD* standard deviation

Comparisons of the CGM parameters showed that the %CV of glycemia (used to allow standardized comparisons between patients with different levels of mean glycemia) was significantly lower in WFS patients (28.08 ± 7.37) compared to T1D patients (37.87 ± 14.24, *p* = 0.029) (Fig. [1](#Fig1){ref-type="fig"}a). A tendency toward a lower SD, as the simplest tool for the assessment of glycemic variability, was found in patients with WFS (41.89 ± 10.34) as compared to T1D (52.40 ± 21.54, *p* = 0.099). All analyzed CGM parameters are summarized in Table [2](#Tab2){ref-type="table"}. Figure [2](#Fig2){ref-type="fig"} shows the differences in glycemic variability between a WFS patient and a T1D patient based on two CGM records which are representative for all studied patients.Fig. 1Comparison of percentage coefficient of variation (%CV) (**a**) and percentage of values above 126 mg/dL (**b**) in CGM between patients with type 1 diabetes (T1D) and Wolfram syndrome (WFS)Table 2Comparison of CGM glycemic variability parameters between the study groupsParameterWFS group (Mean ± SD)T1D group (Mean ± SD)*p* levelMean150.28 ± 14.41138.21 ± 29.380.166Standard deviation41.89 ± 10.3452.40 ± 21.540.099%CV28.08 ± 7.3737.87 ± 14.24**0.029**M100 index12.18 ± 4.8815.58 ± 12.220.305J index37.20 ± 6.8138.16 ± 17.340.837CONGA1h34.29 ± 7.7239.10 ± 14.260.273CONGA2h47.04 ± 9.5258.06 ± 22.030.079CONGA4h54.96 ± 11.9274.12 ± 28.74**0.020**CONGA6h55.99 ± 10.5880.26 ± 35.05**0.009***p* values below 0.05 are marked in bold*%CV* percentage coefficient of variation, *CONGA* continuous net glycemic action, *T1D* type 1 diabetes, *WFS* Wolfram syndromeFig. 2Differences in glycemic variability in CGM records from a patient with type 1 diabetes (*T1D* *dashed line*, average glycemia = 134.03 ± 51.26 mg/dL) and a patient with Wolfram syndrome (*WFS* *solid line*, average glycemia = 148.38 ± 49.78 mg/dL)

Following the above comparisons, we assessed CONGA parameters. CONGA4h and GONGA6h were significantly lower in patients with WFS (54.96 ± 11.92 and 55.99 ± 10.58, respectively) than in patients with T1D (74.12 ± 28.74, *p* = 0.020 and 80.26 ± 35.05, *p* = 0.009, respectively). CONGA2h showed a similar pattern but did not reach statistical significance (*p* = 0.079) (Table [2](#Tab2){ref-type="table"}).

In WFS patients, the percentage of values above 126 mg/dL was 69.79 (52.08--77.43), whereas in T1D patients, it was significantly lower---47.22 (35.07--62.85, *p* = 0.018) (Fig. [1](#Fig1){ref-type="fig"}b). Curiously, there was a tendency toward a smaller percentage of measurements below 70 mg/dL in the WFS group \[0 (0--7.29) %\] compared to the T1D group \[6.25 (0--18.06) %, *p* = 0.122\]. Similar differences were noted for the percentage of nighttime hypoglycemic events, but the difference was not statistically significant (*p* = 0.148). All analyzed percentages are shown in Table [3](#Tab3){ref-type="table"}.Table 3Comparison of percentages of CGM measurements between the study groupsWFS group \[median (25--75 %)\]T1D group \[median (25--75 %)\]*p* level% Above 126 mg/dL (7 mmol/l)69.79 (52.08--77.43)47.22 (35.07--62.85)**0.018**% Above 180 mg/dL (10 mmol/l)19.10 (18.40--35.07)22.92 (12.50--30.9)0.614% Below 70 mg/dL (3.89 mmol/l)0 (0--7.29)6.25 (0--18.06)0.122% Below 54 mg/dL (3 mmol/l)0 (0--1.74)0 (0--2.08)0.816% Of nighttime hypoglycemia \[\<70 md/dl (\<3.89 mmol/l)\]0 (0--3.52)3.04 (0.82--4.63)0.148*p* value below 0.05 is marked in bold*T1D* type 1 diabetes, *WFS* Wolfram syndrome

Discussion {#Sec5}
==========

In this study, glucose variability among diabetic patients with WFS was evaluated for the first time. This condition is rare among patients with diabetes \[[@CR18]\]. In the Polish National Registry, we found 15 patients with diabetes and WFS. For this study, we were able to recruit seven patients from the entirety of Poland, and we compared these with a larger number of patients with T1D (1:3) that we matched using an objective statistical tool. Based on this approach, and using the CGM system, we found lower glycemic variability in pediatric patients with WFS in comparison with T1D patients. Furthermore, an increased percentage of hyperglycemia above 126 mg/dL in WFS patients was also noted. To date, efforts to evaluate the degree of metabolic control of diabetes in WFS relied on the measurement of HbA1c level, which is strongly linked to a risk of chronic complications, frequency of ketoacidosis and partial remission, and episodes of hypoglycemia. However, the literature has reported conflicting results. Some studies demonstrated lower daily insulin requirements and better glycemic control in patients with WFS as compared to T1D \[[@CR14]\]. Rohayem et al. \[[@CR15]\] in a large cohort of patients noted only a higher frequency of ketoacidosis at diabetes onset for T1D than for WFS patients, with a no significant differences in daily insulin dose and clinical remission.

Despite longer periods of hyperglycemia in our study, it should be noted that the glycemic variability of the WFS group was in fact lower than that of the T1D group. Although data on glycemic variability are far from conclusive, there is growing evidence that glycemic variability plays a role in the formation of reactive oxygen species and may increase the rates of diabetic complications \[[@CR19], [@CR20]\]. The reasons behind the lower glycemic variability in WFS patients may be manifold---from more conservative treatment regimens ordered by their doctors to more efficient counter-regulatory mechanisms. We did our best to mitigate the impact of patient selection through the matching procedure and picked groups with similar HbA1c levels and insulin requirements to assure that our measurements of variability would be free from these confounders. It would thus seem more likely that the lower glycemic variability we observed in patients with WFS may be an effect of an intrinsic biological factor rather than of diabetes self-management.

Rohayem et al. \[[@CR15]\] reported a lower prevalence of microvascular complications and a higher frequency of severe hypoglycemia in WFS patients in comparison with T1D patients. In our study, a tendency toward a reduced frequency of hypoglycemia episodes below 70 mg/dL in WFS patients in comparison with T1D patients was observed, whereas the incidence of severe hypoglycemia (below 54 mg/dL) was similar in both study groups.

The observed differences may be related to more efficient secretion of endogenous insulin in WFS than in T1D patients. A persistent insulin secretory reserve could also explain the protection of our WFS patients from significant changes in glycemia levels recorded during CGM. Differences in insulin secretion measured by C-peptide level between these types of diabetes were already reported by some researchers \[[@CR21]\]. Other studies reported different results concerning severe insulin deficiency in both diseases \[[@CR22], [@CR23]\]. However, we confirmed there is preserved residual insulin secretion (based on the concentrations of C-peptide) in WFS patients, but not in T1D individuals.

On the other hand, we would like to emphasize that the reduced incidence of hypoglycemia with an increased percentage of hyperglycemia could be also related to the preserved permanent glucagon response in WFS patients. This hypothesis is consistent with the results obtained in WFS animal models by Ishihara et al. \[[@CR12]\] who demonstrated progressive loss of β-cells in mutant mice while the α-cells were completely preserved. In contrast, other studies have reported that α-cell function and the glucagon response are impaired in patients with T1D \[[@CR24], [@CR25]\].

Unfortunately, we were not able to measure plasma glucagon levels of the patients at the time of the CGM study, which would be a valuable complement to the presented results. Because of this limitation of the study, our observations on the importance of glucagon can be only speculative.

The high frequency of hyperglycemia observed in our study in WFS patients is even more concerning in light of reports of the long-term adverse impact of hyperglycemia on the brain of diabetic patients. Results obtained by Mauras et al. \[[@CR26]\] using high-resolution structural magnetic resonance imaging and the CGM system suggest the presence of disturbances in the structure of gray and white matter of the brain in children with T1D associated with chronic hyperglycemia. Prolonged hyperglycemia can be especially damaging for WFS patients who have many neurodegenerative features detected by neuroimaging studies \[[@CR27], [@CR28]\]. Therefore, every extensive effort to limit the episodes of hyperglycemia among subjects with WFS should be recommended and this information is needed for clinicians who deal with these patients.

In conclusion, our study showed for the first time that patients with WFS have smaller glycemic variability than individuals with T1D, and this is probably associated with persistent residual insulin secretion in WFS.
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